Calafiore R, Basta G, Falorni A, Pietropaolo M, Picchio M L, Calcinaro F, Brunetti P
Laboratorio Insule, Università di Perugia, Italy.
J Endocrinol Invest. 1993 Dec;16(11):869-73. doi: 10.1007/BF03348947.
We have studied the effects of long-term treatment with azathioprine (AZA) vs cyclosporin A (CSA) vs placebo (PL), in three groups of 10 week old, prediabetic NOD mice. One of 8 AZA, none of 8 CSA and 7 of 11 PL treated mice developed overt diabetes (IDDM). Quantitative morphometric analysis conducted on mouse pancreatic histologic sections documented that extent and degree of islet beta-cell damage were incomparably less severe in the mice that received AZA or CSA compared to those treated with PL. Since early and prolonged treatment with AZA seems to prevent the onset of DM in NOD mice as nearly effectively as CSA, AZA, which is significantly safer than CSA, could replace the latter as a potential approach for the immunotherapy of IDDM.
我们研究了硫唑嘌呤(AZA)、环孢素A(CSA)与安慰剂(PL)长期治疗对三组10周龄糖尿病前期非肥胖糖尿病(NOD)小鼠的影响。8只接受AZA治疗的小鼠中有1只、8只接受CSA治疗的小鼠中无一例、11只接受PL治疗的小鼠中有7只发展为显性糖尿病(胰岛素依赖型糖尿病,IDDM)。对小鼠胰腺组织切片进行的定量形态计量分析表明,与接受PL治疗的小鼠相比,接受AZA或CSA治疗的小鼠胰岛β细胞损伤的程度和范围要轻得多。由于早期和长期使用AZA似乎能像CSA一样有效地预防NOD小鼠糖尿病的发生,且AZA比CSA安全得多,因此AZA可以取代CSA作为IDDM免疫治疗的潜在方法。